UMN Pharma is focused on the development and production of recombinant protein vaccines, which are designed to provide effective immunization against various infectious diseases, including COVID-19. The company has achieved significant milestones, such as obtaining domestic manufacturing and sales approval for its COVID-19 vaccine, "Kobugoz®," which is based on a recombinant protein platform. This technology allows for the precise engineering of proteins to elicit a strong immune response, facilitating the production of vaccines that can be scaled up for commercial use. The integration of their vaccine production capabilities, from initial formulation to clinical trial manufacturing and commercial production, enhances operational efficiency and strengthens inter-functional collaboration.

In line with its strategic direction, UMN Pharma has announced plans to transfer its vaccine production business to Shionogi & Co., Ltd. by April 2025, which will streamline their operations and consolidate expertise in vaccine development. This transition aims to unify the production system for recombinant protein vaccines, thereby improving the overall quality and effectiveness of their vaccine offerings. The company is also actively engaged in community initiatives and partnerships, reflecting its commitment to social responsibility and sustainable development goals (SDGs).

Japan

UMN Pharma Co., Ltd. is a bioventure company established in April 2004. The company name is Unmet Medical Needs (UMN), and the company is currently focusing on developing and manufacturing vaccines to prevent infectious diseases.

UMN Pharma

Company Details